Clinical Trials Logo
  1. Home
  2. Efficacy
  3. NCT06196814

AK112 Plus Platinum-based Chemotherapy for EGFR/ALK/ROS1 Positve NSCLC — Apple  

Efficacy Clinical Trial

Official title:
Efficay and Satety of PD-1/VEGR Bispecific Antibodies (AK112) Plus Platinum-based Chemotherapy for EGFR/ALK/ROS1 Positve NSCLC: A Multiple Centers, Multiple Cohorts, Dose Escalation Phase II Apple Study

Clinical Trial Summary

The investigators want to evaluated the Efficay and Satety of PD-1/VEGR bispecific antibodies (AK112) plus Platinum-based Chemotherapy for EGFR/ALK/ROS1 Positve NSCLC who Failed from First-Line Standard Treatment.

Clinical Trial Description

The investigators want to evaluated the Efficay and Satety of PD-1/VEGR bispecific antibodies (AK112) plus Platinum-based Chemotherapy for EGFR/ALK/ROS1 Positve NSCLC who Failed from First-Line Standard Treatment. This study will be devided into three cohorts. Cohort A for EGFR mutation NSCLC, Patient with NGS idenfied EGFR sensitive mutation NSCLC who failed from first line Osimertinib will be included. The 3+3 stud will conducted for dose escalation for AK112 （from 20mg to 30mg), and than the fix dose will be set up for cohort A, B and C. Cohort B for ALK fusion NSCLC, Patient with NGS idenfied ALK fusion NSCLC who failed from first line Alectinib will be included. All the patients will be devided two group,3'ALK and 3'ALK with reteintion of 5'ALK. All the patients will be treated with PD-1/VEGR bispecific antibodies (AK112) plus Platinum-based Chemotherapy. Cohort C for ROS1 fusion NSCLC, Patient with NGS idenfied ROS1 fusion NSCLC who failed from first line crizotinib or Entrectinib will be included. All the patients will be treated with PD-1/VEGR bispecific antibodies (AK112) plus Platinum-based Chemotherapy. The investigators will collect the satety and efficacy data for all the patients. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT06196814
Study type Interventional
Source Hunan Province Tumor Hospital
Contact Yongchang Zhang
Phone +8613873123436
Email zhangyongchang@csu.edu.cn
Status Not yet recruiting
Phase Phase 1/Phase 2
Start date April 1, 2024
Completion date February 1, 2027
View Details
See also
  Status Clinical Trial Phase
Not yet recruiting NCT00944268 - Efficacy and Tolerability Study to Treat Mild and Moderate Anxiety Phase 3
Completed NCT00504192 - A Phase II Study of Gemcitabine With Oxaliplatin as First Line Chemotherapy in Advanced Biliary Tract Cancer Phase 2
Recruiting NCT05580159 - New Generation mRNA Booster Vaccine Against Emerging VOCs Phase 3
Completed NCT05427305 - TAB008 Compared to Avastin® in Patients With EGFR Wild-type Non-squamous Non-small Cell Lung Cancer Phase 3
Active, not recruiting NCT05686161 - mRNA Booster Vaccine(SW-BIC-213) Compared With Pfizer andSinopharm Against Emerging VOCs Phase 3
Recruiting NCT06284746 - Tirelizumab Combined With Chemotherapy in the Treatment of HER-2 Negative Locally Advanced Gastric Cancer Phase 2
Completed NCT04260113 - Apatinib for Inoperable Advanced Chondrosarcoma N/A
Recruiting NCT06120712 - A Phase Ⅰb Study on Autologous GC101 TIL Injection for the Treatment of Advanced Melanoma (MIZAR-002) Phase 1/Phase 2
Active, not recruiting NCT04002440 - Directed Use of REmote Patient Management System AMia to Achieve Prescribed Dry Weight N/A
Recruiting NCT02693587 - Misodel or Angusta for Induction of Labour? N/A
Completed NCT01194453 - Pemetrexed Plus Cisplatin Versus Gemcitabine Plus Cisplatin for Advanced NSCLC Metastatic Non-small Cell Lung Cancer Phase 2
Recruiting NCT05276557 - PyloPlus Urea Breath Test System Pediatric Safety and Efficacy Study Phase 3
Recruiting NCT06205758 - Efficacy and Safety Prediction of Milrinone or Levosimendan as Initial Inotropic Drug Therapy in Patients With Acute and Advanced Heart Failure With Renal Insufficiency
Recruiting NCT06122454 - A Phase Ic/IIb Study to Evaluate the Efficacy，Safety and Pharmacokinetics of HST in Patients With CHB Phase 1/Phase 2
Recruiting NCT05913271 - Study on the Correlation Between NAT2(N-acetyltransferase2) Gene Polymorphism and CrCl(Creatine Clreance) and the Efficacy and Safety of Levosimendan in Patients With Severe Heart Failure
Recruiting NCT05999656 - Human Cord Blood Mononuclear Cells in the Treatment of Refractory Diabetic Foot N/A
Recruiting NCT05731258 - Observational of Adjuvant Treatment of Breast Cancer With Liposomal Doxorubicin Regimen
Recruiting NCT03908138 - RDD Versus VDD in Newly Diagnosed Patients With Multiple Myeloma Phase 4
Completed NCT05648799 - Pharmacokinetics, Safety and Efficacy Study of GP30341 (GEROPHARM, Russia) in Healthy Volunteers and Outpatients With COVID-19 N/A
Recruiting NCT03377933 - The Effects Probiotic Has on Gastromicroecology and Combined With Quadruple Regimen for H Pylori Infection N/A